Project MOA Indication Exploratory research Preclinical Clinical study Partner
Ph1 Ph2 Ph3
SCO-272

Direct renin inhibitor
  • Diabetic
    kidney disease
 

  • Hypertension
   
SCO-792

Enteropeptidase inhibitor
  • Diabetic
    kidney disease
 

  • Phenylketonuria (PKU)
    Maple syrup urine disease (MSUD)
    Homocystinuria (HCU)
   
  • Nephrotic syndrome
   
SCO-267

GPR40 full agonist
  • Diabetes
  • Obesity
  • NASH
   

SCO-094

GLP-1R/GIPR dual agonist
  • Diabetes
  • Obesity
  • NASH
   

Huadong Medicine
SCO-240

SSTR5 antagonist
  • Growth hormone deficiency (GHD)
  • Infertility
  • Alopecia
   

SCO-006

IP6K inhibitor
  • Ovarian clear cell carcinoma
  • Hyperphosphatemia
     

SCO-116

NRF2 activator
  • Ophthalmology and dermatology*
  • Diabetic kidney disease
  • NASH
  • Lung diseases
     

Locally delivered
formulation in ophthalmic
and dermal diseases:
Kuria Therapeutics
(worldwide)
Project A

Undisclosed
(small molecule)
  • Rare endocrine diseases etc.
     

Project B

Undisclosed
(peptide)
  • Lymphoedema etc.
       

Project C

Undisclosed
(small molecule)
  • Undisclosed
       

The compound code starts with SCO-,
and is given to a compound to be used in a GLP study.

*SCOHIA is actively seeking a development and commercialization partner for any of our assets. Contact here for partnering.

We are committed to building a portfolio of innovative
and sufficient R&D pipelines centered on the field of lifestyle-related diseases.

Our basic R&D strategy is to select different mechanism of action among projects at
each development stage, and to ensure that other compounds (backup compounds)
are considered in projects at the preclinical study stage,
which minimizes the development risk and
continuously enhances the drug candidate stage.

Process of drug discovery

Exploratory research

Selection of drug
discovery targets

Select the target (such as protein) for the drug to work.

Screening

Screen lead compounds as potential drug seeds according to the strength of binding to the target, toxicity, and other factors.

Lead compound optimization

Select the best compound after lead compounds are repeatedly converted.

Preclinical study

Pharmacology study

Lowest effective dose?

Pharmacokinetic study

How is it absorbed, distributed, metabolized, and excreted in the body?

General pharmacology study

How does it work in the body?

General toxicity study

Does it have strong toxicity or harmful effects?

Specific toxicity study

Does it have carcinogenicity or an effect on the fetus?

Investigational New Drug Application (IND)
Clinical study

Phase 1 study

Examine the safety in a small number of healthy volunteers.

Phase 2 study

Examine the efficacy and safety in a relatively small number of patients.
(Determine the dosing regimen, etc.)

Phase 3 study

Systematically examine whether a new drug candidate is worth developing in a large number of patients.

Marketing approval/launch